2012
DOI: 10.1586/egh.12.56
|View full text |Cite
|
Sign up to set email alerts
|

An update on the diagnosis and management of Budd–Chiari syndrome

Abstract: Budd-Chiari syndrome is a rare disorder caused by hepatic venous outflow obstruction and resulting hepatic dysfunction. Despite a lack of prospective randomized trials, much progress has been made in its management over the last 20 years. The main goals of treatment are to ameliorate hepatic congestion and prevent further thrombosis. The selective use of anticoagulation, vascular stents, transjugular intrahepatic portosystemic stent-shunt and liver transplant has resulted in a significant increase in survival.… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
45
0

Year Published

2014
2014
2017
2017

Publication Types

Select...
6
1

Relationship

0
7

Authors

Journals

citations
Cited by 37 publications
(45 citation statements)
references
References 78 publications
0
45
0
Order By: Relevance
“…From the viewpoint of patient costs, balloon dilation alone minimizes the operative cost and procedure complexity, making it a more appropriate first-choice endovascular treatment for patients with MOVC. Moreover, the complications of long-term indwelling stents, such as stent fracture, migration to the heart, and occlusion of the ostium of the hepatic or accessory hepatic veins, 26,27 serve as a reminder that caution should be used when choosing and placing stents in BCS patients with MOVC.…”
Section: Discussionmentioning
confidence: 99%
“…From the viewpoint of patient costs, balloon dilation alone minimizes the operative cost and procedure complexity, making it a more appropriate first-choice endovascular treatment for patients with MOVC. Moreover, the complications of long-term indwelling stents, such as stent fracture, migration to the heart, and occlusion of the ostium of the hepatic or accessory hepatic veins, 26,27 serve as a reminder that caution should be used when choosing and placing stents in BCS patients with MOVC.…”
Section: Discussionmentioning
confidence: 99%
“…3,[5][6][7] Idiopathic forms, combined membranous occlusion of the inferior vena cava and the hepatic veins, and higher incidence of hepatocellular carcinoma are typical features of most Chinese BCS patients. [5][6][7][8] In addition, selection of treatment modalities for BCS patients is different between China and Western countries.…”
Section: -7mentioning
confidence: 99%
“…[5][6][7][8] In addition, selection of treatment modalities for BCS patients is different between China and Western countries. 3,9,10 Chinese patients with BCS are usually treated using percutaneous transluminal angioplasty and have a similar good clinical outcome to Western patients, who often are treated with transjugular intrahepatic portosystemic shunt plus long-term anticoagulants. 9,10 As an update, there have been around 3000 articles on BCS in China, but the real prevalence might be higher than estimated due to increased awareness and improved diagnostic methods in China.…”
Section: -7mentioning
confidence: 99%
See 1 more Smart Citation
“…Budd-Chiari syndrome (BCS) is caused by hepatic venous obstruction and/or inferior vena cava obstructive lesions above the junction, and belongs to a type of posthepatic portal hypertension characterized by portal hypertension and/or inferior vena cava hypertension (MacNicholas et al, 2012). In China, BCS is the most common type of membranous obstruction of the inferior vena cava (MOVC) whose development is characterized by septum formation above the junction of the inferior vena cava and hepatic veins with vascular endothelial tissues on both the upper and lower surfaces of the septum.…”
Section: Introductionmentioning
confidence: 99%